Latest news

Insights

AI in Medical Affairs: How Pharma Is Becoming a Real-Time Scientific Intelligence System

Executive Summary Medical affairs is undergoing a structural transformation that goes far beyond digital enablement or workflow automation. It is...
Insights

Are Pharmaceutical Companies Moving Too Fast With AI Adoption?

Executive Summary Artificial intelligence is rapidly becoming embedded across nearly every layer of the pharmaceutical industry. Drug discovery, clinical trial...
Commercial

For CAR-T biotech InnocsAI, struggling Liminatus pays $320 million in equity

Liminatus Pharma, a company specializing in cancer immunotherapies, has agreed to give up shares valued at $320 million to...
Clinical

After a phase 2 failure, Biogen ends Parkinson’s prospects with Denali

Biogen and Denali Therapeutics announced that their Parkinson's disease drug candidate failed to meet the primary endpoint of a...
Clinical

Kelun Reports Positive Phase 3 Results for sac-TMT With Keytruda in First-Line NSCLC

Merck’s Chinese partner Kelun-Biotech has reported positive Phase 3...
Insights

From Pilots to Scale: Why Most Healthcare AI Projects Stall

Executive Summary Healthcare organizations have invested heavily in artificial intelligence...
Insights

Why Life Sciences Leaders Are Reassessing Their Cloud Strategies

Executive Summary Cloud computing has become foundational to modern life sciences infrastructure. Pharmaceutical companies, biotech firms, healthcare organizations, and research...
Research & Development

Early research shows that Lilly’s Verve strategy is successful in lowering cholesterol

The pharma's $1.3 billion bet on the base editor last year when it acquired Verve Therapeutics was rewarded by...
Commercial

Lilly Pens $3.8B Deal to Purchase 3 Vaccine Developers Amidst M&A Spree

Eli Lilly has committed up to $3.8 billion to expand into infectious disease research, acquiring three biotech companies, namely...
Clinical

Agios Halts Tebapivat Development in LR-MDS After Phase 2b Trial Misses Primary Endpoint

Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator tebapivat has failed a phase 2b study in lower-risk myelodysplastic syndromes (LR-MDS),...
Insights

How Smaller Biotech Firms Are Competing With Big Pharma Using AI

Executive Summary Artificial intelligence is beginning to reshape competitive dynamics across the pharmaceutical and biotechnology industry. For decades, large pharmaceutical companies...
Insights

The AI Talent War in Life Sciences Is Just Beginning

AI Talent:Executive Summary Artificial intelligence is no longer a tooling upgrade in life sciences—it is becoming a labor constraint problem...
Regulatory

FDA Approves Datroway for First-Line Triple-Negative Breast Cancer in Certain Patients

The competition among TROP2-targeting therapies in first-line triple-negative breast...
Editorial Team -
Commercial

For CAR-T biotech InnocsAI, struggling Liminatus pays $320 million in equity

Liminatus Pharma, a company specializing in cancer immunotherapies, has...
Editorial Team -

Popular

Most popular life news you must read today

View all articles

Commercial

Information Technology

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

Chugai Pharmaceutical has entered into a research collaboration with Singapore-based Gero to develop antibody-based...
Editorial Team -

J&J MedTech presents the first Ottava surgical robot clinical cases

Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot...
Editorial Team -

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal...
Editorial Team -

PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm

Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers...
Editorial Team -

Regulatory

Regulatory

FDA Approves Datroway for First-Line Triple-Negative Breast Cancer in Certain Patients

The competition among TROP2-targeting therapies in first-line triple-negative breast...
Editorial Team -
Insights

Are Pharmaceutical Companies Moving Too Fast With AI Adoption?

Executive Summary Artificial intelligence is rapidly becoming embedded across nearly...
Commercial

For CAR-T biotech InnocsAI, struggling Liminatus pays $320 million in equity

Liminatus Pharma, a company specializing in cancer immunotherapies, has...
Clinical

After a phase 2 failure, Biogen ends Parkinson’s prospects with Denali

Biogen and Denali Therapeutics announced that their Parkinson's disease...
Regulatory

FDA Approves Datroway for First-Line Triple-Negative Breast Cancer in Certain Patients

The competition among TROP2-targeting therapies in first-line triple-negative breast...

Research & Development

Market Access

Manufacturing

Cellares Raises $257 Million Series D to Expand Global Cell Therapy Manufacturing

Cellares has raised $257 million in a Series D...
Manufacturing

Recipharm Commissions Bengaluru Facility for Nonbacterial Beta-Lactam Tablet Manufacturing

Swedish contract development and manufacturing organization (CDMO) Recipharm has...

Manufacturing & RegulatoryPOPULAR
Find Your Perfect Music Festival

Insights

AI in Medical Affairs: How Pharma Is Becoming a Real-Time Scientific Intelligence System

Executive Summary Medical affairs is undergoing a structural transformation that...
Editorial Team -
Commercial

For CAR-T biotech InnocsAI, struggling Liminatus pays $320 million in equity

Liminatus Pharma, a company specializing in cancer immunotherapies, has...
Editorial Team -